HPV疫苗接种规划的人群影响与群体效应:更新系统综述与荟萃分析
该更新系统综述与荟萃分析纳入14个高收入国家的65篇文章,评估HPV疫苗接种对HPV感染、肛门生殖器疣诊断及CIN2+的人群影响。接种5-8年后,13-19岁女孩HPV 16/18患病率下降83%,15-19岁女孩肛门生殖器疣诊断下降67%;接种5-9年后,15-19岁女孩CIN2+下降51%。多队列接种且高覆盖率的规划直接影响和群体效应更大。
要点
- 接种5-8年后13-19岁女孩HPV 16/18患病率下降83%(RR 0·17,95%CI 0·11-0·25)。
- 接种5-8年后15-19岁女孩肛门生殖器疣诊断下降67%(RR 0·33,95%CI 0·24-0·46)。
- 接种5-9年后15-19岁女孩CIN2+下降51%(RR 0·49,95%CI 0·42-0·58)。
核心结论
- HPV疫苗接种规划对女孩和女性的HPV感染及CIN2+、对女孩女性男孩和男性的肛门生殖器疣诊断具有显著人群影响。
- 多队列接种且高覆盖率的规划具有更大的直接影响和群体效应。
研究设计与样本
- 更新系统综述与荟萃分析,检索MEDLINE和Embase 2014年2月1日至2018年10月11日发表的研究。
- 纳入比较接种前后普通人群至少一项HPV相关终点频率的研究,共纳入14个高收入国家的65篇文章:HPV感染23篇、肛门生殖器疣29篇、CIN2+ 13篇。
- 采用随机效应模型估计汇总相对危险度(RR),按性别、年龄和接种后年数分层分析。
主要发现
- 接种5-8年后,13-19岁女孩HPV 16/18患病率下降83%(RR 0·17,95%CI 0·11-0·25),20-24岁女性下降66%(RR 0·34,95%CI 0·23-0·49)。
- 接种5-8年后,13-19岁女孩HPV 31/33/45患病率下降54%(RR 0·46,95%CI 0·33-0·66)。
- 接种5-8年后,15-19岁女孩肛门生殖器疣诊断下降67%(RR 0·33,95%CI 0·24-0·46),20-24岁女性下降54%(RR 0·46,95%CI 0·36-0·60),25-29岁女性下降31%(RR 0·69,95%CI 0·53-0·89)。
- 接种5-8年后,15-19岁男孩肛门生殖器疣诊断下降48%(RR 0·52,95%CI 0·37-0·75),20-24岁男性下降32%(RR 0·68,95%CI 0·47-0·98)。
- 接种5-9年后,15-19岁筛查女孩CIN2+下降51%(RR 0·49,95%CI 0·42-0·58),20-24岁女性下降31%(RR 0·69,95%CI 0·57-0·84)。
关键数值与推荐
- 纳入标准为比较接种前后普通人群至少一项HPV相关终点(生殖道HPV感染、肛门生殖器疣诊断或组织学确诊CIN2+)频率且接种前后使用相同人群来源和招募方法的研究。
- 主要评估指标为接种前后HPV相关终点频率(患病率或发病率)的相对危险度(RR)。
临床怎么用
- 支持HPV疫苗接种规划在真实世界中显著降低HPV感染、肛门生殖器疣和CIN2+的人群负担。
- 多队列接种和高接种覆盖率可增强直接保护和群体效应。
局限性
- 纳入研究均来自高收入国家,结果外推至其他地区需谨慎。
- 接种后随访时间最长为8年,长期影响尚未覆盖。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More than 10 years have elapsed since human papillomavirus (HPV) vaccination was implemented. We did a systematic review and meta-analysis of the population-level impact of vaccinating girls and women against human papillomavirus on HPV infections, anogenital wart diagnoses, and cervical intraepithelial neoplasia grade 2+ (CIN2+) to summarise the most recent evidence about the effectiveness of HPV vaccines in real-world settings and to quantify the impact of multiple age-cohort vaccination. METHODS: In this updated systematic review and meta-analysis, we used the same search strategy as in our previous paper. We searched MEDLINE and Embase for studies published between Feb 1, 2014, and Oct 11, 2018. Studies were eligible if they compared the frequency (prevalence or incidence) of at least one HPV-related endpoint (genital HPV infections, anogenital wart diagnoses, or histologically confirmed CIN2+) between pre-vaccination and post-vaccination periods among the general population and if they used the same population sources and recruitment methods before and after vaccination. Our primary assessment was the relative risk (RR) comparing the frequency (prevalence or incidence) of HPV-related endpoints between the pre-vaccination and post-vaccination periods. We stratified all analyses by sex, age, and years since introduction of HPV vaccination. We used random-effects models to estimate pooled relative risks. FINDINGS: We identified 1702 potentially eligible articles for this systematic review and meta-analysis, and included 65 articles in 14 high-income countries: 23 for HPV infection, 29 for anogenital warts, and 13 for CIN2+. After 5-8 years of vaccination, the prevalence of HPV 16 and 18 decreased significantly by 83% (RR 0·17, 95% CI 0·11-0·25) among girls aged 13-19 years, and decreased significantly by 66% (RR 0·34, 95% CI 0·23-0·49) among women aged 20-24 years. The prevalence of HPV 31, 33, and 45 decreased significantly by 54% (RR 0·46, 95% CI 0·33-0·66) among girls aged 13-19 years. Anogenital wart diagnoses decreased significantly by 67% (RR 0·33, 95% CI 0·24-0·46) among girls aged 15-19 years, decreased significantly by 54% (RR 0·46, 95% CI 0.36-0.60) among women aged 20-24 years, and decreased significantly by 31% (RR 0·69, 95% CI 0·53-0·89) among women aged 25-29 years. Among boys aged 15-19 years anogenital wart diagnoses decreased significantly by 48% (RR 0·52, 95% CI 0·37-0·75) and among men aged 20-24 years they decreased significantly by 32% (RR 0·68, 95% CI 0·47-0·98). After 5-9 years of vaccination, CIN2+ decreased significantly by 51% (RR 0·49, 95% CI 0·42-0·58) among screened girls aged 15-19 years and decreased significantly by 31% (RR 0·69, 95% CI 0·57-0·84) among women aged 20-24 years. INTERPRETATION: This updated systematic review and meta-analysis includes data from 60 million individuals and up to 8 years of post-vaccination follow-up. Our results show compelling evidence of the substantial impact of HPV vaccination programmes on HPV infections and CIN2+ among girls and women, and on anogenital warts diagnoses among girls, women, boys, and men. Additionally, programmes with multi-cohort vaccination and high vaccination coverage had a greater direct impact and herd effects. FUNDING: WHO, Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé.
引用
- Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019. PMID: 31255301. doi:10.1016/S0140-6736(19)30298-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。